Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRF6019 in mild to moderate Alzheimer's disease
NCT03520998Phase 2Completed
- Sponsor
- Alkahest, Inc.
- Start
- Apr 2018
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of GRF6019 in Alzheimer's disease (AD), sponsored by Alkahest, Inc.. Started Apr 2018; status: completed.
02
Drugs
GRF6019
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03520998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520998.